A Study of SHR-2173 in Participants With Primary IgA Nephropathy

Summary

This study is a randomized, double-blind, placebo-controlled Phase II clinical trial to evaluate the efficacy and safety of SHR-2173 in patients with Primary IgA Nephropathy(IgAN). The study consists of a screening period, a run-in period, a 48-week double-blind treatment period, and a 12-week follow-up period. Approximately 84 IgAN patients will be included.

Timeline

Start

2026-03-09

Primary completion

2027-04

Completion

2027-12

Drugs

Indications